×
About 6,268 results

ALLMedicine™ Mantle Cell Lymphoma Center

Research & Reviews  1,670 results

Real-World Treatment Patterns and Outcomes of Mantle Cell Lymphoma.
https://doi.org/10.1182/bloodadvances.2022007247
Blood Advances; Narkhede M, Goyal G et. al.

May 14th, 2022 - Mantle cell lymphoma (MCL) is considered incurable with the available chemoimmunotherapy approaches, and therefore newer, effective targeted therapies such as Bruton Tyrosine Kinase (BTK) inhibitors are increasingly used in MCL as chronic suppress...

New Directions for Mantle Cell Lymphoma in 2022.
https://doi.org/10.1200/EDBK_349509
American Society of Clinical Oncology Educational Book. A... Kumar A, Eyre TA et. al.

May 14th, 2022 - Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma Interna...

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

May 13th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory MCL
https://clinicaltrials.gov/ct2/show/NCT05370430

May 11th, 2022 - This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating patients with Mantle Cell Lymphoma (MCL) that has come back (recurrent) or does not respond to treatment (refractory). T cells are infection fighting bloo...

see more →

Guidelines  3 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines fo...
https://doi.org/10.1093/annonc/mdx223
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Campo E et. al.

Sep 9th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,

Non-Hodgkin's lymphomas, version 4.2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839265
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Sep 6th, 2014 - Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL case...

see more →

Drugs  24 results see all →

Clinicaltrials.gov  131 results

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

May 13th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory MCL
https://clinicaltrials.gov/ct2/show/NCT05370430

May 11th, 2022 - This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating patients with Mantle Cell Lymphoma (MCL) that has come back (recurrent) or does not respond to treatment (refractory). T cells are infection fighting bloo...

Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03888105

May 10th, 2022 - Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by indepen...

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04930536

May 10th, 2022 - A prospective, multi-centre, phase IV clinical trial of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL). As per recommendation from Indian health autho...

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL
https://clinicaltrials.gov/ct2/show/NCT04624958

May 9th, 2022 - This phase 2 trial studies the efficacy and safety of zanubrutinib plus rituximab followed by R-DHAOx (rituximab, dexamethasone, cytarabine and oxaliplatin) regimen then maintenance with zanubrutinib for newly-diagnosed Mantle Cell Lymphoma (MCL).

see more →

News  679 results

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl

May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma
https://www.onclive.com/view/car-nk-cell-therapies-show-preliminary-safety-and-efficacy-in-aml-non-hodgkin-lymphoma

Apr 25th, 2022 - The novel allogeneic CAR-engineered natural killer (NK) cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia (AML) and non-Hodgkin ...

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL
https://www.onclive.com/view/dr-dietrich-on-optimizing-treatment-options-for-patients-in-mcl

Apr 12th, 2022 - Martin Dietrich, MD, PhD, physician, Florida Cancer Specialists and Research Institute, assistant professor of internal medicine, University of Central Florida, discusses optimizing treatment options for patients with mantle cell lymphoma (MCL). ...

Dr. Dietrich on the Current Treatment Landscape of MCL
https://www.onclive.com/view/dr-dietrich-on-the-current-treatment-landscape-of-mcl

Apr 1st, 2022 - Martin Dietrich, MD, PhD, physician, Florida Cancer Specialists and Research Institute, assistant professor of internal medicine, University of Central Florida, discusses the current treatment landscape of mantle cell lymphoma (MCL). Treatment op...

FISH Testing Guides Treatment of CLL: New Drugs on Horizon
https://www.onclive.com/view/fish-testing-guides-treatment-of-cll-new-drugs-on-horizon

Mar 15th, 2022 - Susan O'Brien, MD Fluorescence in situ hybridization (FISH) testing for genetic abnormalities is the key to appropriate treatment selection for patients with chronic lymphocytic leukemia (CLL), according to Susan M. O’Brien, MD, professor of Med...

see more →